Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACC-001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 3 μg ACC-001 / QS-21 50 μg IM dose 1 | EXPERIMENTAL | 3 μg ACC-001 / QS-21 50 μg IM |
| 10 μg ACC-001 / QS-21 50 μg IM dose 2 | EXPERIMENTAL | 10 μg ACC-001 / QS-21 50 μg IM |
| Placebo - Phosphate buffered saline (PBS) IM dose | NO_INTERVENTION | Placebo - Phosphate buffered saline (PBS) IM |
| Name | Type | Description |
|---|---|---|
| ACC-001 (vanutide cridificar) | BIOLOGICAL | Comparisons of 2 different doses of ACC-001 or placebo for 24 months |
Inclusion Criteria: * Diagnosis of probable AD * Age from 50 to 89 * Mini-Mental Status Exam score of 18-26 inclusive * Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD * Stable doses of medications (cholinesterase inhibitors and memantine allowed) * Caregiver able to...
Top 20 of 24 competitors
ACC-001 is an investigational monoclonal antibody being developed for the treatment of Alzheimer's Disease. It is intended for patients with mild to moderate Alzheimer's Disease, as studied in a Phase 2 clinical trial. The drug is not yet approved and remains in clinical development.
ACC-001 is a monoclonal antibody, but its specific molecular target has not been disclosed in the available information. The drug is being studied for its effects on Alzheimer's Disease, and the clinical trial included amyloid imaging to assess its impact on amyloid plaques in the brain.
ACC-001 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for Alzheimer's Disease.
ACC-001 is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug is not yet approved by regulatory authorities. It remains an investigational agent, and further studies may be needed to establish its safety and effectiveness.
ACC-001 has been studied in one completed Phase 2 clinical trial, identified as NCT01284387. This trial, titled 'Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease,' enrolled 126 participants in the United States and was a randomized, double-blind, no-treatment-controlled study.
ACC-001 is not known to have any alternative names. It is a distinct investigational monoclonal antibody being developed by Johnson & Johnson for Alzheimer's Disease. No other names for this drug have been reported in the available information.